PT  - JOURNAL ARTICLE
AU  - Yin, Rong
AU  - Yang, ZhiQi
AU  - Wei, YaXuan
AU  - Li, YuanMing
AU  - Chen, Hui
AU  - Liu, Zhao
AU  - Zhao, Bo
AU  - Ma, DanDan
AU  - Dan, MeiLing
AU  - Zhang, YingJie
AU  - Liu, Xuan
AU  - Leng, HuiCeng
AU  - Xiang, DaWei
TI  - Clinical characteristics of 106 patients with neurological diseases and co-morbid coronavirus disease 2019: a retrospective study
AID  - 10.1101/2020.04.29.20085415
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.29.20085415
4099  - http://medrxiv.org/content/early/2020/05/10/2020.04.29.20085415.short
4100  - http://medrxiv.org/content/early/2020/05/10/2020.04.29.20085415.full
AB  - Objectives To describe the clinical characteristics of patients with coronavirus disease 2019 (COVID-19) with co-morbid neurological symptoms.Design Retrospective case series.Setting Huoshenshan Hospital in Wuhan, China.Participants From 4 February to 14 April 2020, 106 patients with neurological diseases were enrolled from all patients in the hospital with confirmed COVID-19 and divided into a severe group and a non-severe group according to their COVID-19 diagnosis.Main outcome measures Clinical characteristics, laboratory results, imaging findings, and treatment methods were all retrieved through an electronic medical records system and recorded in spreadsheets.Results The mean (standard deviation, SD) age of patients was 72.7 (11.8) years, and 64 patients were male (60.4%). Among patients with co-morbid neurological diseases, 81 had a previous cerebral infarction (76.4%), 20 had dementia (18.9%), 10 had acute cerebral infarction (9.4%), 5 had sequelae of cerebral haemorrhage (4.7%), 4 had intracranial mass lesions (3.8%), 3 had epilepsy (2.8%), 2 had Parkinson’s disease (1.9%), and 1 had myelopathy (0.9%). Fever (n = 62, 58.5%) was the most common symptom. The most common neurological symptoms were myalgia (n = 26, 24.5%), followed by extremity paralysis (n = 20, 18.9%), impaired consciousness (n = 17, 16%), and positive focal neurological signs (n = 42, 39.6%). Eight patients (7.5%) died. There were more patients with altered mental status in the severe group than in the non-severe group (6 [10.2%] vs. 0, P = 0.033). The inflammatory response in the severe group was more significant than that in the non-severe group. There were more patients taking anticoagulant drugs (25 [42.4%] vs. 4 [8.5%], P < 0.001) and sedative drugs (22 [37.3%] vs. 9 [19.1%], P = 0.041) in the severe group than in the non-severe group. Amid all 93 patients with cerebrovascular diseases, only 32 (34.4%) were taking aspirin, 13 (14%) taking clopidogrel, and 33 (35.5%) taking statins.Conclusions Patients with COVID-19 with co-morbid neurological diseases had an advanced age, a high rate of severe illness, and a high mortality rate. Among the neurological symptoms, altered mental status was more common in patients with severe COVID-19 with co-morbid neurological diseases.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: support from the Huoshenshan Hospital for Scientific research Project and the Top project of PLA youth cultivation program, for the submitted work; no financial relationships with any organization that might have an interest in the submitted work in the previous three years; we thank webshop of elsevier (https://webshop.elsevier.com) for its linguistic assistance during the preparation of this manuscript; no other relationships or activities that could appear to have influenced the submitted work.Funding StatementThis work was funded by grants from the Huoshenshan Hospital for Scientific research Project (HSSYYKYMSKT-244) and partly supported by the Top project of PLA youth cultivation program (18QNP053), National Commission of Health, People’s Republic of China. The research was designed, conducted, analysed, and interpreted by the authors entirely independently of the funding sources.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are available from the corresponding author upon request.